During the clinical demo working experience with Xyrem in narcolepsy/cataplexy patients at therapeutic doses, two patients reported anxiety and just one documented sleeplessness subsequent abrupt discontinuation with the termination on the scientific trial; in The 2 individuals with anxiety, the frequency of cataplexy experienced increased markedly at the same time. https://lorenzoozipi.blogitright.com/36612370/considerations-to-know-about-flubromazolam-effects